Dyadic International (DYAI) Cost of Revenue (2018 - 2025)
Dyadic International's (DYAI) quarterly Cost of Revenue came in at $297658.0 in Q1 2025, up 106.77% year-over-year from $143955.0 in Q1 2024, and down 15.63% quarter-over-quarter from $352819.0 in Q4 2024.
Analysis
Dyadic International (DYAI) Cost of Revenue (2018 - 2025) Analysis & Trends
Dyadic International has disclosed Cost of Revenue across 8 years of filings, most recently posting $297658.0 for Q1 2025.
- In Q1 2025, Cost of Revenue rose 106.77% year-over-year to $297658.0; the TTM figure through Mar 2025 stood at $1.3 million (down 3.2% YoY), while the FY2024 annual figure was $1.2 million, down 39.54% from the prior year.
- Cost of Revenue came in at $297658.0 for Q1 2025 at Dyadic International, down from $352819.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $390.8 million in Q1 2021 to a low of $105869.0 in Q3 2023.
- Average Cost of Revenue over 5 years is $23.4 million, with a median of $395894.0 recorded in 2024.
- Year-over-year, Cost of Revenue jumped 140369.91% in 2021 and sank 99.9% in 2022.
- Over 5 years, Cost of Revenue stood at $331628.0 in 2021, then surged by 112.43% to $704491.0 in 2022, then slumped by 50.3% to $350118.0 in 2023, then advanced by 0.77% to $352819.0 in 2024, then retreated by 15.63% to $297658.0 in 2025.
- Per Business Quant data, the three most recent Cost of Revenue figures were $297658.0 in Q1 2025, $352819.0 in Q4 2024, and $395894.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn | 2.81 Bn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | 1.58 Bn |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn | 489.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn | 360.70 Mn |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn | 145.00 Mn |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn | 93.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn | 776.90 Mn |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn | 284,000.00 |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 297,658.00 |
| Dec 31, 2024 | 352,819.00 |
| Sep 30, 2024 | 395,894.00 |
| Jun 30, 2024 | 301,956.00 |
| Mar 31, 2024 | 143,955.00 |
| Dec 31, 2023 | 350,118.00 |
| Sep 30, 2023 | 105,869.00 |
| Jun 30, 2023 | 792,944.00 |
| Mar 31, 2023 | 726,918.00 |
| Dec 31, 2022 | 704,491.00 |
| Sep 30, 2022 | 602,847.00 |
| Jun 30, 2022 | 411,109.00 |
| Mar 31, 2022 | 404,746.00 |
| Dec 31, 2021 | 331,628.00 |
| Sep 30, 2021 | 392,544.00 |
| Jun 30, 2021 | 829,504.00 |
| Mar 31, 2021 | 390.76 Mn |
| Dec 31, 2020 | 255,580.00 |
| Sep 30, 2020 | 266,929.00 |
| Jun 30, 2020 | 624,240.00 |